At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09688 ZAI LAB
Market Closed 06-26 16:08:11
13.910
-0.560
-3.87%
High14.490
Low13.620
Vol13.24M
Open14.470
D1 Closing14.470
Amplitude6.01%
Mkt Cap15.83B
Tradable Cap15.83B
Total Shares1.14B
T/O185.16M
T/O Rate1.16%
Tradable Shares1.14B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Movement Alert｜Zai Lab Falls 5.04% in Regular Trading, Partner Novocure Clinical Failure Continues to Weigh on Sentiment
Zai Lab Receives China Nmpa Approval of Tivdak® (Tisotumab Vedotin for Injection) for the Treatment of Adult Patients With Recurrent or Metastatic Cervical Cancer
HK Movers | Biotech Stocks Jump. Asymchem up Nearly 7%; SKB Bio up About 6%; Hengrui Pharma, Pharmaron, InnoGen up over 4%; Wuxi Apptec up 3%; Laekna, Joinn, Remegen up over 2%
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.